A growing consensus is emerging among obesity experts: the healthcare system—not the therapy—is the biggest bottleneck in obesity care.
As GLP-1 demand surges, traditional specialist-led models are breaking down under volume. Referral centers are overwhelmed, prior authorizations are consuming entire teams, and access remains uneven—revealing a system not designed for a disease affecting millions.
The proposed shift is clear: move from siloed care to a distributed, multidisciplinary model where primary care, pharmacists, dietitians, and specialists share ownership—similar to how diabetes is managed today.
But scaling care isn’t just about access. It’s about coordination:
- Pharmacists and techs handling the PA burden
- Shared medical appointments expanding reach
- Nutrition and strength training addressing quality of weight loss
- Systems integrating obesity care with comorbidities like MASH and cardiovascular disease
At the same time, a hard truth persists: access—not side effects—is the leading reason patients discontinue GLP-1s, driven by cost, coverage, and supply constraints.
The long-term vision? Treat obesity like cancer—through coordinated, multidisciplinary centers offering personalized pathways, not fragmented interventions.
In essence, GLP-1s didn’t just change treatment—they exposed the need to rebuild the entire care delivery model around obesity.